Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Go back to Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 218.11 +2.61 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $215.50 | 52 Week High | $333.65 | |||
| Open | $216.14 | 52 Week Low | $223.02 | |||
| Day High | $218.72 | P/E | 27.93 | |||
| Day Low | $214.59 | EPS | $7.81 | |||
| Volume | 80,312 | |||||
| (NASDAQ: BIIBV) | Delayed: 259.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $259.61 | 52 Week High | $ | |||
| Open | $0.00 | 52 Week Low | $ | |||
| Day High | $259.61 | P/E | N/A | |||
| Day Low | $259.61 | EPS | $ | |||
| Volume | 19,000 | |||||
